Furthermore, patients with adenocarcinoma and EGFR mutations showed a longer overall survival than did patients with squamous cell carcinoma and without EGFR mutation (p=0.021 and p=0.038, respectively). This evidence concerns the gene EGFR and squamous cell carcinoma.